Antisense oligonucleotides to c-myb oncogene and uses thereof
CA 2004364 C · Owner: Gewirtz, Alan M. · Inventors: Gewirtz, Alan M.; Calabretta, Bruno
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Abstract of the Disclosure, Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These "antisense" oligonucleotides are hybridizable to the c-myb mRNA transcript. Such oligonucleotides are useful in treating hematologic neoplasms and in inducing immunosuppression. They are particularly useful as bone marrow purging agents. 6056-72 (CIP)2 CN, /tep
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 1, 1989 and granted August 31, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 1, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 1, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.